Many organic impurities, such as nitrosamines, are known to be harmful to human health. Therefore, regulatory bodies and government set strict limits to protect us all. Even in small quantities, pharmaceutical impurities can have serious negative health impacts and influence the behaviour and efficacy of a drug. Organic impurities fall into a number of categories.

We spoke to chemists at different stages of their careers about their experiences of attending our ‘Chemical Development and Scale Up in the Fine Chemical and Pharmaceutical Industries’ training course. Ben Littler  Ben told us that he had taken the ‘Chem Dev’ course twice as an early career process chemist!  Both courses were held as

Do you have a topic that you would like to share with our international audience of organic chemists? We are currently inviting speakers to present technical papers at our events this year.   Flow Chemistry & Continuous Processing Conference – ONLINE – 10-11 May Catalysis in the Fine Chemicals Industries Conference – ONLINE – 2-3

Dr John Studley (JS) spoke to Heather Johnson (HJ) from Merck ahead of Heather’s presentation at our Organic Process Research & Development Conference. JS – The Science paper describing the design of a biocatalytic cascade for the manufacture of Islatravir (Science 2019, 366, 1255,) published by Merck and Codexis at the end of last year, represents

Dr John Studley (JS) from Scientific Update spoke to Dr David Barnes (DB) from Abbvie in the US  ahead of our ‘Organic Process Research and Development’ Conference which is taking place in Clearwater, Florida on 9-11 March. We are looking forward to your presentation ‘Discovery of Novel Catalytic Technologies in the Development of Complex Clinical